- Bloomberg•3 years ago
Bayer AG, the inventor of Aspirin, is marketing its biggest bond sale in Europe since at least 2009 after borrowing costs fell to the lowest in more than seven months.
- Reuters•3 years ago
OSLO/LONDON (Reuters) - Bayer (BAYN.DE) has offered to pay $2.4 billion for Norway's Algeta (ALGETA.OL), its partner for a new prostrate cancer treatment, at a 27 percent premium to the stock's last close, Algeta said on Tuesday. The deal would boost Bayer's drugs division by giving it outright control over Xofigo, a drug the two have developed jointly since 2009 and started selling in the United States this year. Investors, however, bet that the German drugs and chemicals group has a fight on its hands and Algeta's Chief Financial Officer said that rival bids could not be ruled out. Algeta shares jumped by a third in early trade to a record 349.7 Norwegian crowns, well above Bayer's bid of 336 crowns.
We're sorry this is all we were able to find about this topic.
Oslo - Oslo Delayed Price. Currency in NOK
As of 10:38 AM EST. Market open.
|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||360.00 - 362.00|
|52wk Range||360.00 - 362.00|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||N/A|
|Avg Vol (3m)||N/A|
|Dividend & Yield||N/A (N/A)|